AbbVie's Q2 IPR&D Expenses and Its Impact on EPS

Wednesday, 3 July 2024, 18:55
AbbVie announced a projected impact on its earnings per share in the second quarter due to acquired IPR&D and milestone expenses totaling $937 million. The expenses are expected to decrease AbbVie's EPS by $0.52. This financial move highlights the company's strategic investments and financial performance for the quarter.
Seeking Alpha
AbbVie's Q2 IPR&D Expenses and Its Impact on EPS

AbbVie Second Quarter Financial Update

AbbVie (ABBV) revealed plans to record a significant expense of $937 million related to acquired IPR&D and milestone payments in the second quarter. This substantial financial commitment will result in a reduction of $0.52 in the company's earnings per share.

Do you want to advertise here? Contact us

Related posts

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe